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ABSTRACT
Background: Carisoprodol is a skeletal muscle relaxant indicated for use in the 
treatment of acute, painful musculoskeletal conditions. Two randomized, controlled 
clinical trials have reported that carisoprodol 250 mg QID was equally effective as and 
better tolerated than carisoprodol 350 mg QID.
Objectives: The primary objective of the current study was to determine the 
relative bioavailability of carisoprodol and its metabolite, meprobamate, with single-
dose administration of 250- and 350-mg tablets. A secondary objective of the study 
was to determine whether lowering the carisoprodol dose would decrease plasma mepro-
bamate concentrations.
Methods: This single-dose, randomized, open-label, crossover study enrolled 
healthy volunteers. Each dose was administered with water in the morning; after a 
7-day washout, subjects received the alternate dose. Blood samples were drawn at 
prespecified times over a 48-hour period. For tolerability assessment, subjects under-
went a physical examination, including 12-lead ECG.
Results: A total of 24 subjects were enrolled (12 men, 12 women; mean age, 
22.8 years). The dose-adjusted AUC0–∞ values for carisoprodol were 5.29 μg/mL/h 
with the 250-mg tablet and 5.75 μg/mL/h with the 350-mg tablet (relative bioavail-
ability, 92%). The mean (SD) Cmax values of carisoprodol and meprobamate after ad-
ministration of the 250-mg carisoprodol tablet were 1.24 (0.49) and 1.84 (0.31) μg/mL, 
respectively, compared with 1.78 (0.97) and 2.46 (0.47) μg/mL with the 350-mg 
tablet. AUC0–∞ was dose proportional, and the apparent t1/2 values at the terminal 
phase were 1.74 hours with the 250-mg tablet and 1.96 hours with the 350-mg 
tablet. There were 3 mild adverse events considered possibly treatment related (weak-
ness, dizziness, and drowsiness); these were reported in 2 subjects with 350-mg 
carisoprodol.
Conclusions: In this small study in healthy fasting subjects, the exposure to 
carisoprodol and meprobamate was dose proportional between the single 250- and 
350-mg doses. Both doses were generally well tolerated. (Curr Ther Res Clin Exp. 
2010;71:50–59) © 2010 Excerpta Medica Inc.
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INTRODUCTION
Acute musculoskeletal spasm of the back is a common disorder that causes localized 
pain, stiffness, reduced mobility, impaired activities of daily living, and sleep distur-
bances.1 Painful back spasm is a leading cause of physician visits and health expendi-
tures in the United States.2–4 Approximately 15% to 20% of the US population has 
a painful back condition, accounting for 15 to 17 million office visits each year.3,5,6 
The financial impact of these conditions, including direct and indirect costs, has been 
estimated at US $100 billion a year.5,7,8 These epidemiologic and economic data do 
not delineate the numbers for acute musculoskeletal spasm, but studies confirm that 
NSAIDs and skeletal muscle relaxants are the most common initial intervention for 
the management of acute low back pain.3,6,9
Skeletal muscle relaxants are a heterogeneous group of medications used to treat 2 types 
of underlying conditions—spasticity from upper motor neuron syndromes and mus-
cular pain or spasms from peripheral musculoskeletal conditions.6 These drugs are 
used for the short-term relief of acute painful muscle spasms, but strong evidence sup-
porting their long-term use is lacking.10
Carisoprodol is a centrally acting skeletal muscle relaxant indicated for the relief 
of discomfort associated with acute, painful musculoskeletal conditions in adults. 
Carisoprodol was approved for use in the United States in 1959 at a dosage of 350 mg 
TID and at bedtime. According to the manufacturer, treatment should not exceed 
3 weeks.11
Meprobamate, a carisoprodol metabolite, is commercially available for the treat-
ment of anxiety, and when used at its therapeutic dosage, it has been associated with 
misuse and a potential for dependence.12,13 Because of this risk for abuse, this product 
is scheduled by the US Food and Drug Administration (FDA) as a category IV con-
trolled substance. Carisoprodol, however, is not scheduled as a controlled substance by 
the FDA. Monitoring via the FDA adverse-events reporting system and the safety 
database of the manufacturer, in place since January 1979, suggests that reports of 
abuse with carisoprodol are rare (64 reports of drug abuse and drug dependence in the 
manufacturer’s safety database over 3 decades). The most common adverse events re-
ported with carisoprodol use are drowsiness (350-mg tablet, 16.1%; 250-mg tablet, 
12.2%) and dizziness (350-mg tablet, 6.8%; 250-mg tablet, 5.9%).14
Clinical experience with carisoprodol suggests that doses lower than 350 mg QID 
could provide adequate symptom relief with fewer adverse events. Two randomized, 
double-blind clinical studies in 1390 patients with acute low back spasm reported 
that 7-day treatment with carisoprodol 250 mg TID and at bedtime was effective in 
providing relief of low back spasm compared with placebo, with a numerically lower 
prevalence of adverse events compared with a 350-mg dose TID and at bedtime.14,15 
Effectiveness was measured using 2 coprimary end points (P ≤ 0.005 vs placebo for 
global impression of change and P < 0.001 vs placebo for relief from starting back-
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ache). Those studies led to FDA approval of carisoprodol 250 mg in September 
2007.11
The primary objective of the current study was to determine the relative bioavail-
ability of carisoprodol and its metabolite, meprobamate, of the 250- and 350-mg 
doses. A secondary objective of the study was to determine whether lowering the 
carisoprodol dose would decrease plasma meprobamate concentrations.
SUBJECTS AND METHODS
Study Design
This single-dose, randomized, open-label, crossover study was conducted in accor-
dance with the Guideline for Good Clinical Practice and the Declaration of Helsinki. 
The study protocol was approved by an independent institutional review board for 
the study site (Biokinetic Clinical Applications, Inc., Springfield, Missouri). Written 
informed consent was obtained from each subject before participation.
Study Population
Healthy male and female volunteers who were nonsmokers, between 18 and 40 years 
of age, and within ±15% of desirable body weight in relation to height (based on the 
Metropolitan Life Insurance tables) were included in the study. Subjects were screened 
within 14 days of study initiation. Clinical laboratory values, including complete 
blood count with differential, liver function tests, creatinine and blood urea nitrogen, 
serum electrolytes, and urinalysis, were required to be within normal limits, as was 
the 12-lead ECG. Volunteers were excluded if they had a history of or any current 
medical or surgical condition that might significantly alter the absorption, distribu-
tion, metabolism, or excretion of the study drug. Additional exclusion criteria were 
the use of any investigational drug or prescription medication within 30 days of study 
entry (with the exception of oral contraceptives); use of any nonprescription medica-
tion, including all over-the-counter medications, vitamins, and herbal supplements, 
within 14 days of study entry; and/or a urine drug screen result that was positive for 
any drug of abuse. In addition, women who may have been pregnant or were breast-
feeding and women of childbearing potential who were not abstinent or practicing a 
medically acceptable method of contraception were excluded from participation. A 
serum pregnancy test was administered at screening, and urinary pregnancy tests were 
repeated before the administration of each dose of the study drug.
Study Drug Administration
A computer-generated randomization schedule was used to sequentially assign sub-
jects to a randomly ordered treatment sequence. Each subject received a single dose of 
the 250- and 350-mg dose of carisoprodol, with a 7-day washout between study peri-
ods. Each dose was administered in the morning, after a 10-hour fast, with 240 mL 
of water at room temperature. No food or water was allowed for 2 hours after admin-
istration of the study drug, and food was not served until 4 hours after administration. 
Grapefruit products, alcohol, and caffeine-containing beverages and foods were not 
allowed 2 days before administration and during the in-house periods. 
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Pharmacokinetic Assessments
Blood samples for the measurement of carisoprodol and meprobamate concentra-
tions were drawn by direct venipuncture before and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 
6, 8, 10, 12, 16, 24, 30, 36, and 48 hours after each dose into tubes containing EDTA 
(Vacutainer, Becton, Dickinson and Company, Franklin Lakes, New Jersey). Plasma 
was separated by centrifugation under refrigerated conditions, placed into labeled 
tubes, frozen at –20°C, and shipped to a reference laboratory (Cedra Corporation, 
Austin, Texas) for analysis.
Extracted samples were analyzed using an LC-MS/MS (Sciex API 3000, Applied 
Biosystems, Foster City, California) in positive ion mode equipped with an HPLC 
column. The method was validated for a range of 0.010 to 2.500 μg/mL for cariso- 
prodol and 0.008 to 2.000 μg/mL for meprobamate. High, medium, and low quality 
control (QC) samples were prepared for carisoprodol and meprobamate and stored at 
–20°C in 0.10-mL aliquots. Six samples from each QC pool were processed in each 
validation run. Short-term stability studies from thawed QC samples were run for 
triplicate samples left at room temperature for 24 hours before extraction. Quantita-
tion was conducted using a least squares regression analysis generated from calibration 
standards prepared immediately before each run. The lower limits of quantitation 
were 0.010 μg/mL for carisoprodol and 0.008 μg/mL for meprobamate. 
Tolerability Assessment
For tolerability assessment, subjects underwent a physical examination, including 
12-lead ECG, after the completion of the study. All adverse events, regardless of the 
relationship to the study drug, were recorded from screening until the end of the 
study. Adverse events included any event that occurred during the study period, re-
gardless of causality. All adverse events were rated by the investigator as mild, moder-
ate, or severe, and as unlikely, possibly, or probably related to the study medication.
Pharmacokinetic and Statistical Analyses
Pharmacokinetic parameters determined included Cmax, Tmax, AUC0–t, AUC0–∞, 
apparent rate constant of the terminal disposition phase (λz), and apparent half-life λz 
(t1/2λz).
Subjects who completed both treatment periods and had adequate pharmacoki-
netic data were included in the pharmacokinetic population for statistical analysis. 
Tolerability analyses included all randomized subjects who received ≥1 dose of study 
medication. Standard noncompartmental methods were used to calculate the plasma 
pharmacokinetic properties for carisoprodol and meprobamate. The means (SDs) and 
%CVs were calculated for all of the measured pharmacokinetic parameters, as were 
the median, maximum, and minimum values. The geometric mean was estimated for 
the ratio of least squares mean (LSM) AUC0–∞ of the 250-mg carisoprodol tablet 
to the LSM AUC0–∞ of the 350-mg carisoprodol tablet. The ratio (F) was the rela- 
tive bioavailability of the 250- and 350-mg tablets. The LSMs were derived using 
ANOVA. The square root of the mean (SE) from the ANOVA was used for tests and 
for determining the 90% CIs. The mean (90% CI) ratios of the differences were cal-
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Twenty-four subjects were enrolled (12 men, 12 women; mean age, 22.8 years). All 
of the subjects completed both periods of the study and were included in both the 
pharmacokinetic and tolerability populations. The baseline demographic and clinical 
characteristics of the subjects are shown in Table I.
Pharmacokinetic Parameters
The dose-adjusted AUC0–∞ values for carisoprodol were 5.29 μg/mL/h with the 
250-mg tablet and 5.75 μg/mL/h with the 350-mg tablet (F, 92%) (Table II). The 
dose-adjusted geometric mean Cmax values were 1.61 and 1.54 μg/mL with the 250- 
and 350-mg tablets, respectively. The plasma concentration–time curves for each 
dose are shown in the figure, and the mean pharmacokinetic properties are shown in 
Table III. AUC0–∞ was dose proportional, and the t1/2λz values were 1.74 hours with 
the 250-mg tablet and 1.96 hours with the 350-mg tablet.
The meprobamate pharmacokinetic estimates also were dose related (Figure and 
Table III). Meprobamate Cmax was reached ~3.6 and 4.5 hours after the administra-
tion of 250- and 350-mg carisoprodol, respectively. Cmax values for meprobamate after 
Table I.  Baseline demographic and clinical characteristics of the 
study population (N = 24).
Characteristic Value
Age, y  
  Mean (SD) 22.8 (5.3)
  Range 18–40
Sex, no. (%) 
  Male 12 (50)
  Female 12 (50)
Race, no. (%) 
  White 23 (95.8)
  Other 1 (4.2)
Ethnicity, no. (%) 
  Non-Hispanic 19 (79.2)
  Hispanic  5 (20.8)
Height, mean (SD), cm 174 (9)
Weight, mean (SD), kg 72 (13)
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administration of the 250- and 350-mg carisoprodol doses were 1.84 and 2.46 μg/mL, 
and the mean (SD) t1/2 values were similar between the 2 doses (9.67 [1.73] and 9.63 
[1.53] hours, respectively).
Tolerability
There were no clinically significant findings, as determined by the investigator, on 
physical examination, vital sign measurements, or 12-lead ECG. None of the results 
from laboratory analyses were considered by investigators as clinically significant. A 
total of 3 treatment-emergent adverse events considered possibly related to the study 
drug were reported in 2 subjects (8.3%) after the administration of the 350-mg dose. 
These events—weakness, dizziness, and drowsiness—all were mild, and resolved 
without treatment.
DISCUSSION
In this study in healthy subjects, the carisoprodol 250-mg tablet had pharmacokinetic 
properties that were dose proportional to those of the 350-mg tablet. The rate and 
extent of carisoprodol absorption appeared to be comparable between the 2 tablet 
strengths when adjusted for dose. Meprobamate Cmax was reached 3 to 4 hours after 
administration, and the Cmax and AUC0–∞ values were proportional by dose.
Meprobamate, marketed in the United States for the treatment of anxiety, is clas-
sified as schedule IV based on its known potential for abuse. Therefore, it has been 
suggested that the abuse and/or dependence potential of carisoprodol may be related 
to its metabolite, meprobamate.17 The Cmax of meprobamate after the administra- 
tion of a single dose of 400 mg (the marketed tablet strength in the United States) is 
~8 μg/mL.18 The mean (SD) Cmax for meprobamate after the administration of a single 
dose of carisoprodol 250 mg was 1.8 (0.3) μg/mL, which is >4-fold less than the value 
reported for meprobamate 400 mg. The clinical significance of this observation over 
time is unknown. The carisoprodol prescribing information recommends that cariso-
prodol be used with caution in patients with the potential for addiction and in those 
who use other central nervous system depressants, including alcohol, and that use not 
exceed 3 weeks for the relief of acute musculoskeletal discomfort.11
Table II.  Relative bioavailability (F) of carisoprodol with single-dose administration of 
oral carisoprodol 250 or 350 mg in healthy subjects (N = 24).* Values are dose-
adjusted geometric mean unless otherwise specified.
 Carisoprodol Carisoprodol 
Parameter 250 mg 350 mg F (90% CI), %
Cmax, µg/mL 1.61 1.54 104.3 (91.3–119.1)
AUC0–t, µg/mL/h 5.23 5.69 91.9 (85.5–98.8)
AUC0–∞, µg/mL/h 5.29 5.75 92.0 (85.7–98.8)
* Based on dose-adjusted AUC0–t, the exposure to meprobamate with carisoprodol 250 mg was 98% to 
99% of that with 350 mg.
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The findings from this study suggest dose-proportional exposure to both cariso- 
prodol and meprobamate after the administration of a single dose of 250 or 350 mg. 
The lower dose of carisoprodol was associated with a proportionally decreased expo-
sure to meprobamate. This single-dose pharmacokinetic assessment was not designed 
to determine clinical effect, but the reduced meprobamate concentrations were con-
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Figure.  Mean plasma concentration–time curves of (A) carisoprodol and (B) its active 
metabolite, meprobamate, with single-dose administration of oral carisoprodol 
250 or 350 mg in healthy subjects (N = 24).
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2 previously published studies that compared carisoprodol 250 and 350 mg in pa-
tients with acute musculoskeletal spasm of the lower back.14,15
Numerically lower rates of sedation (12.2% vs 16.1%) and dizziness (5.9% vs 
6.8%) were reported with 7-day treatment with carisoprodol 250 mg than with 
carisoprodol 350 mg in a previously published randomized, double-blind study in 
806 patients with acute low back muscle spasm. During that study period, none of 
the patients who received the 250-mg dose reported severe drowsiness, but 2 patients 
discontinued the use of carisoprodol 350 mg because of moderate to severe drowsi-
ness.14 The rates of sedation and dizziness in a randomized, placebo-controlled trial of 
carisoprodol 250 mg were 13.4% and 4.65%, respectively, in patients with acute 
musculoskeletal spasm of the lower back.15 
This single-dose, open-label pharmacokinetic study enrolled 24 healthy volunteers 
who were relatively young and predominantly white, which may limit the generaliz-
ability of the data to other populations (eg, elderly patients, patients with hepatic or 
renal impairment, patients of nonwhite race). There were no clinical end points in this 
study and therefore no need for blinding or a control group. A sample size of 24 sub-
jects was chosen empirically to provide a sufficient number of subjects. Bioavailability 
studies are typically conducted with 16 to 30 subjects. This study was designed only 
to assess the relative bioavailability of carisoprodol and meprobamate after the admin-
istration of single 250- and 350-mg doses of carisoprodol, and the results should be 
interpreted in that context.
CONCLUSIONS
The findings from this small study in healthy fasting subjects suggest that the cari-
soprodol 250-mg tablet was 92% bioavailable relative to the 350-mg tablet after 
Table III.  Pharmacokinetic properties of carisoprodol and its active metabolite, mepro-
bamate, with single-dose administration of oral carisoprodol 250 or 350 mg in 
healthy subjects (N = 24). Values are mean (SD) unless otherwise specified.
 250 mg 350 mg
Parameter Carisoprodol Meprobamate Carisoprodol Meprobamate
Cmax, µg/mL 1.24 (0.49) 1.84 (0.31) 1.78 (0.97) 2.46 (0.47)
Tmax, h 
  Mean (SD) 1.5 (0.8) 3.6 (1.7) 1.7 (0.8) 4.5 (1.9)
  Median (range) 1.5 (0.75–4.0) 3.0 (2.0–10.0) 1.5 (0.75–4.0) 4.0 (2.0–10.0)
λz, h–1 0.429 (0.114) 0.074 (0.013) 0.374 (0.088) 0.074 (0.012)
t1/2λz, h 1.74 (0.52) 9.67 (1.73) 1.96 (0.52) 9.63 (1.53)
AUC0–t, µg/mL/h 4.46 (3.06) 31.06 (5.58) 6.94 (4.96) 44.08 (8.18)
AUC0–∞, µg/mL/h 4.51 (3.07) 32.33 (6.20) 7.00 (4.97) 45.98 (8.98)
λz = apparent rate constant of the terminal disposition phase; t1/2λz = apparent half-life at λz.
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single-dose administration. The pharmacokinetic properties of both carisoprodol and 
meprobamate were dose proportional between the 250- and 350-mg carisoprodol 
doses. Both doses were generally well tolerated.
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